Datt Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.25 Cr
as on 26-06-2024
- Paid Up Capital ₹ 1.60 M
as on 26-06-2024
- Company Age 13 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2022)
- Profit 3.14%
(FY 2022)
- Ebitda 4.51%
(FY 2022)
- Net Worth -1.51%
(FY 2022)
- Total Assets -0.38%
(FY 2022)
About Datt Life Sciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.25 Cr and a paid-up capital of Rs 1.60 M, as per Ministry of Corporate Affairs (MCA) records.
Gita Datt, Rajan Datt, and Ruchita Datt serve as directors at the Company.
- CIN/LLPIN
U73100DL2011PTC292542
- Company No.
292542
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jul 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
South Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Datt Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ruchita Datt  | Director | 20-Nov-2021 | Current |
Gita Datt  | Director | 11-Jul-2011 | Current |
| Rajan Datt | Director | 11-Jul-2011 | Current |
Financial Performance and Corporate Structure Insights of Datt Life Sciences.
Datt Life Sciences Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 3.14% increase in profit. The company's net worth dipped by a decrease of 1.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Datt Life Sciences?
In 2022, Datt Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Brahm Datt Investments & Finance Co Pvt LtdActive 40 years 11 monthsGita Datt and Rajan Datt are mutual person
- Datt Mediproducts Private LimitedActive 29 years 10 months
Gita Datt and Ruchita Datt are mutual person
- Datt Capital Services Private LimitedActive 29 years 10 months
Gita Datt and Rajan Datt are mutual person
Czar Infrastructure Private LimitedActive 18 years 9 monthsGita Datt and Rajan Datt are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Datt Life Sciences?
Unlock and access historical data on people associated with Datt Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Datt Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Datt Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
